Humana (HUM) Q2 2025 Earnings Transcript

Humana raised full-year 2025 adjusted EPS guidance to approximately $17 from $16.25, citing stronger-than-expected CenterWell Pharmacy performance and better individual Medicare Advantage retention. Management said medical cost trends are tracking in line to better than expectations, while membership decline improved to up to 500,000 from 550,000 previously. The company also added about $100 million of incremental investment, completed $100 million of buybacks, and repurchased about $200 million of 2027 debt, but Stars litigation and proposed home health reimbursement cuts remain key risks.

Analysis

The market is likely underestimating how much of the near-term upside is now becoming self-reinforcing: better MA retention reduces the severity of adverse selection, which in turn improves pricing confidence and lowers the probability of another destructive benefit reset. That matters because Humana’s biggest swing factor is no longer just membership count, but the quality of the book entering 2026; bounce-back members and improved recapture suggest the company is stabilizing the risk pool rather than merely buying growth. If that dynamic holds through AEP/OEP, the earnings trajectory can improve even without a dramatic step-up in top-line enrollment.

The more important second-order read is that CenterWell Pharmacy is becoming a meaningful internal hedge against MA margin volatility. Direct-to-consumer and specialty access expansion add a mix shift that is less exposed to pure utilization politics than core insurance, and the company’s willingness to pull some investment forward suggests management sees unusually high marginal returns in retention and care-navigation tools. That should help medium-term multiple support, but it also means 2025-2026 EPS is somewhat less clean than the headline guidance implies because execution risk is now spread across more moving pieces.

The biggest unresolved overhang is regulatory: Stars litigation, RADV, and home health reimbursement are all potentially asymmetric, but on different time horizons. Near term, the stock can re-rate if investors believe the 2027 Stars risk is contained and 2026 bid assumptions are de-risked; over 6-12 months, however, any evidence that the richer-benefit gap narrows faster than expected could pressure retention and margin simultaneously. The contrarian view is that the consensus is still treating Humana like a damaged MA insurer when it increasingly behaves like a managed healthcare platform with a growing services/pharmacy earnings engine and more disciplined capital allocation.

Key Decisions for Investors

• Long HUM on a 3-6 month horizon ahead of AEP/OEP: upside comes from continued membership stabilization and Pharmacy-led guidance durability; risk/reward improves if the market has been overly punitive on Stars and MA churn.
• Pair trade: long HUM / short a more benefit-rich MA peer that has not yet reset pricing enough for 2026; thesis is that tighter product design plus retention discipline will outperform undisciplined growth over the next 2-3 quarters.
• Buy HUM Jan-2026 calls or call spreads on pullbacks: event path is AEP/OEP, CMS bid clarity, and litigation updates; limited downside versus a potential multiple expansion if the market starts to price a cleaner 2026 earnings base.
• Fade enthusiasm if HUM rallies sharply into Stars-related catalysts: trim long exposure into strength because the next 60-90 days still carry binary headline risk around preview data, litigation process, and regulatory interpretation.
• Watch for a relative-value long HUM vs. hospital/home-health exposed names: Humana has a partial hedge against home health pressure through insurance and can use operating leverage/outsourcing to offset reimbursement noise better than pure providers.